Reid, M. Et Al. 2020. Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%. 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) , (Los-Angeles, Chile), 1673.

Reid, M., Balci, S., BAĞCI ÇULÇİ, P., Saka, B., Pehlivanoglu, B., ERBARUT SEVEN, İ., ... Basturk, O.(2020). Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5% . 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) (pp.1673). Los-Angeles, Chile

Reid, Michelle Et Al. "Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%," 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), Los-Angeles, Chile, 2020

Reid, Michelle Et Al. "Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%." 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) , Los-Angeles, Chile, pp.1673, 2020

Reid, M. Et Al. (2020) . "Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%." 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) , Los-Angeles, Chile, p.1673.

@conferencepaper{conferencepaper, author={Michelle Reid Et Al. }, title={Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%}, congress name={109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)}, city={Los-Angeles}, country={Chile}, year={2020}, pages={1673} }